<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090505</url>
  </required_header>
  <id_info>
    <org_study_id>GC-ChinaPLAGH-2010</org_study_id>
    <nct_id>NCT01090505</nct_id>
  </id_info>
  <brief_title>Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer</brief_title>
  <official_title>Phase 2 Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether S-1 and oxaliplatin as neoadjuvant
      chemotherapy may improve survival benefit compared with control.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Drug:S-1:80mg/m2;oxaliplatin 130mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Neoadjuvant chemotherapy(S-1+Oxaliplatin) followed by D2 gastrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Procedure/Surgery: Gastrectomy with D2 dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: S-1 and oxaliplatin</intervention_name>
    <description>Drug:S-1:80mg/m2;oxaliplatin 130mg/m2</description>
    <arm_group_label>Drug:S-1:80mg/m2;oxaliplatin 130mg/m2</arm_group_label>
    <arm_group_label>surgery</arm_group_label>
    <other_name>S-1:Taiho</other_name>
    <other_name>Oxaliplatin：sanofi-aventis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. DISEASE CHARACTERISTICS:

             Histologically confirmed gastric adenocarcinoma Locally advanced disease:Clinical
             stage T3-4, N0-3, M0 (according to the Japanese gastric cancer classification)

          2. Planning to undergo gastric cancer D2 surgery after neoadjuvant chemotherapy

          3. Age:20 to 75

          4. Performance status:ECOG 0-2

          5. Life expectancy:Not specified

          6. Hematopoietic:WBC 4,000-12,000/mm^3；Granulocyte count ≥ 2,000/mm^3；Platelet count ≥
             100,000/mm^3；Hemoglobin ≥ 9.0 g/dL;Hepatic:AST and ALT ≤ 100 U/L；Bilirubin ≤ 1.5 mg/dL

          7. Adequate organ function

          8. Able to swallow oral medication

          9. Written informed consent

        Exclusion Criteria:

          1. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ

          2. Pregnant or breast-feeding women

          3. Severe mental disease

          4. Systemic administration of corticosteroids, flucytosine, phenytoin or warfarin

          5. Other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary
             fibrosis, or ischemic heart disease

          6. Myocardial infarction within six disease-free months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>L Chen, MD</last_name>
    <phone>86-10-66938028</phone>
    <email>litbj301@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fu xing road 28#</last_name>
      <phone>86-10-66938328</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2010</study_first_posted>
  <last_update_submitted>March 19, 2010</last_update_submitted>
  <last_update_submitted_qc>March 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>L Chen</name_title>
    <organization>Chinese PLA General Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

